Which statin is appropriate for a 62-year-old patient with total cholesterol 245 mg/dL, LDL cholesterol 150 mg/dL, triglycerides 276 mg/dL, HDL cholesterol 46 mg/dL, VLDL cholesterol 49 mg/dL, and an LDL/HDL ratio of 3.3?

Statin Recommendation for 62-Year-Old with Dyslipidemia

Start a high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) immediately to achieve an LDL-C reduction of ≥50% and target LDL-C <70 mg/dL, with consideration of adding icosapent ethyl 4g daily given the elevated triglycerides.

Risk Stratification

This 62-year-old patient falls into a high cardiovascular risk category based on:

• LDL-C 150 mg/dL (significantly above goal)
• Triglycerides 276 mg/dL (markedly elevated)
• Non-HDL-C 199 mg/dL (calculated as total cholesterol minus HDL)
• Atherogenic dyslipidemia pattern (elevated TG with borderline low HDL at 46 mg/dL)

The most recent 2023 ADA guidelines 1 and 2019 ACC/AHA guidelines 2, 3 establish that for individuals aged 40-75 with multiple cardiovascular risk factors, high-intensity statin therapy is the standard of care.

Primary Statin Selection

High-intensity statin options 1:

• Atorvastatin 40-80 mg daily - achieves >50% LDL-C reduction
• Rosuvastatin 20-40 mg daily - achieves >50% LDL-C reduction

The 2022 AACE/NAFLD guidelines 4 specifically recommend moderate-to-high intensity statins as first-line therapy, with high-intensity preferred for patients with multiple risk factors. Given this patient's LDL-C of 150 mg/dL and elevated triglycerides, high-intensity therapy is warranted from the start rather than titrating up from moderate-intensity.

Why High-Intensity Over Moderate-Intensity?

The patient needs approximately 50% LDL-C reduction to reach the <70 mg/dL goal for high-risk individuals 4, 1. Moderate-intensity statins (atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg) only achieve 30-49% LDL-C reduction 1, which would be insufficient.

Addressing the Elevated Triglycerides

The triglyceride level of 276 mg/dL requires specific attention beyond statin therapy:

According to 2022 AACE guidelines 4:

• For TG 135-499 mg/dL with established CVD risk factors: Add icosapent ethyl 4g daily to statin therapy
• This combination has proven cardiovascular event reduction in the REDUCE-IT trial

The 2019 ACC/AHA guidelines 3 support adding icosapent ethyl in patients with triglycerides between 135-499 mg/dL who are on statin therapy and have diabetes or established ASCVD.

Alternative Triglyceride Management

If icosapent ethyl is not available or tolerated 4, 5:

• Fenofibrate can be considered after statin therapy is optimized (not before)
• Prescription omega-3 fatty acids (EPA+DHA 3-4g daily) can reduce triglycerides by 20-50%
• Avoid gemfibrozil due to increased rhabdomyolysis risk when combined with statins 6

Target Goals and Monitoring

Primary goal: LDL-C <70 mg/dL 4, 1 Secondary goal: Non-HDL-C <100 mg/dL 4 Triglyceride goal: <150 mg/dL 4

Monitoring Schedule 7, 3:

1. Baseline: Obtain fasting lipid panel, ALT, creatinine, HbA1c (if diabetes suspected)
2. 4-12 weeks: Repeat lipid panel to assess response
3. Every 3-12 months: Ongoing monitoring once stable
4. Monitor for: Muscle symptoms, liver enzyme elevations (though progression to liver failure is exceedingly rare 8)

If Goals Not Achieved on Maximum Statin

If LDL-C remains ≥70 mg/dL on maximally tolerated high-intensity statin 2, 3:

1. Add ezetimibe 10 mg daily (first choice - safest, well-tolerated)
2. If still not at goal, consider PCSK9 inhibitor (though cost-effectiveness is a consideration 2)
3. Bempedoic acid is an alternative for statin-intolerant patients 4

Critical Pitfalls to Avoid

• Do not use fibrates as monotherapy for this lipid profile - statins must be the foundation 5
• Avoid gemfibrozil-statin combinations due to rhabdomyolysis risk; fenofibrate is safer if fibrate needed 6, 5
• Do not delay statin initiation for lifestyle modification alone at this risk level - start both simultaneously 9, 3
• Do not use niacin routinely - it may worsen insulin resistance and has not shown cardiovascular benefit in recent trials 4, 5

Lifestyle Modifications (Concurrent with Statin)

Per 2022 AACE guidelines 4:

• Increase fiber intake to 25g daily
• Mediterranean diet pattern emphasizing vegetables, fruits, whole grains, nuts
• Reduce saturated fat to <7% of calories
• Limit added sugars
• Regular physical activity (30-60 minutes most days)

The evidence strongly supports that this patient requires high-intensity statin therapy initiated immediately, with the addition of icosapent ethyl given the elevated triglycerides and cardiovascular risk profile.